Neurofibromatosis 1 in childhood
- PMID: 9874851
- DOI: 10.1016/s1071-9091(98)80002-8
Neurofibromatosis 1 in childhood
Abstract
Neurofibromatosis 1 (NF1) is an autosomal-dominant disorder with an incidence of approximately 1 in 3,000. The cardinal features of the disorder are cafe au lait spots, axillary freckling, cutaneous neurofibromas, and iris hamartomas (Lisch nodules). Common complications include learning disability, scoliosis, and optic gliomas. Other complications (e.g., peripheral nerve malignancy, bony deformities, and epilepsy) are individually rare. The mainstay of care for patients with NF1 is anticipatory guidance, and the early detection and symptomatic treatment of disease complications. Counseling of patients and their families should provide a realistic overview of possible disease complications, while emphasizing that most individuals with NF1 lead healthy and productive lives. The gene for NF1 has been identified, and future cell biology research will focus on understanding the pathogenetic mechanisms that underly the diverse manifestations of the disorder.
Similar articles
-
[Neurofibromatosis--an inborn genetic disorder with susceptibility to neoplasia].Med Wieku Rozwoj. 2006 Jul-Sep;10(3 Pt 2):923-48. Med Wieku Rozwoj. 2006. PMID: 17401183 Review. Polish.
-
Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.J Dermatol. 2020 Jun;47(6):658-662. doi: 10.1111/1346-8138.15327. Epub 2020 Apr 4. J Dermatol. 2020. PMID: 32246533
-
Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.Postgrad Med. 2019 Sep;131(7):445-452. doi: 10.1080/00325481.2019.1659708. Epub 2019 Sep 12. Postgrad Med. 2019. PMID: 31443616
-
[Clinical diagnosis of neurofibromatosis type 1].Presse Med. 1999 Dec 11;28(39):2174-80. Presse Med. 1999. PMID: 10629698 French.
-
Neurofibromas in children with neurofibromatosis 1.J Child Neurol. 2002 Aug;17(8):585-91; discussion 602-4, 646-51. doi: 10.1177/088307380201700808. J Child Neurol. 2002. PMID: 12403557 Review.
Cited by
-
Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.Health Qual Life Outcomes. 2013 Feb 21;11:21. doi: 10.1186/1477-7525-11-21. Health Qual Life Outcomes. 2013. PMID: 23432799 Free PMC article.
-
Selumetinib-A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis.Indian Dermatol Online J. 2024 Jun 26;15(4):701-705. doi: 10.4103/idoj.idoj_569_23. eCollection 2024 Jul-Aug. Indian Dermatol Online J. 2024. PMID: 39050082 Free PMC article. No abstract available.
-
Adaptive behavior in young children with neurofibromatosis type 1.Int J Pediatr. 2013;2013:690432. doi: 10.1155/2013/690432. Epub 2013 Nov 19. Int J Pediatr. 2013. PMID: 24348581 Free PMC article.
-
Neurocognitive dysfunction in children with neurofibromatosis type 1.Curr Neurol Neurosci Rep. 2003 Mar;3(2):129-36. doi: 10.1007/s11910-003-0064-3. Curr Neurol Neurosci Rep. 2003. PMID: 12583841 Review.
-
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.Clin Cancer Res. 2024 Oct 1;30(19):4363-4376. doi: 10.1158/1078-0432.CCR-24-0797. Clin Cancer Res. 2024. PMID: 39093127 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous